David B. Straus

David B. Straus

Auto-generated profile, based on publicly available information

David B. Straus

Department of Biology, Virginia Commonwealth University , Richmond, VA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
EKElizabeth Motunrayo Kolawole
Elizabeth Motunrayo Kolawole
JMJamie Josephine Avila McLeod
Jamie Josephine Avila McLeod
VNVictor Ndaw
Victor Ndaw
DADaniel Abebayehu
Daniel Abebayehu
BBBrian O Barnstein
Brian O Barnstein
JRJohn Joseph Ryan
John Joseph Ryan
Mast cell (MC)– and basophil-associated inflammatory diseases are a considerable burden to society. A significant portion of patients have symptoms despite standard-of-care therapy. Statins, used to lower serum cholesterol, have immune-modulating activities. We tested the in vitro and in vivo effects of statins on IgE-mediated MC and basophil activation. Fluvastatin showed the most significant inhibitory effects of the six statins tested, suppressing IgE-induced cytokine secretion among mouse MCs and basophils. The effects of fluvastatin were reversed by mevalonic acid or geranylgeranyl pyrophosphatase, and mimicked by geranylgeranyl transferase inhibition. Fluvastatin selectively suppressed key FcεRI signaling pathways, including Akt and ERK. Although MCs and basophils from the C57BL/6J mouse strain were responsive to fluvastatin, those from 129/SvImJ mice were completely resistant. Resistance correlated with fluvastatin-induced upregulation of the statin target HMG-CoA reductase. Human MC cultures from eight donors showed a wide range of fluvastatin responsiveness. These data demonstrate that fluvastatin is a potent suppressor of IgE-mediated MC activation, acting at least partly via blockade of geranyl lipid production downstream of HMG-CoA reductase. Importantly, consideration of statin use for treating MC–associated disease needs to incorporate genetic background effects, which can yield drug resistance.

27 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
JBJason Ray Burchett
Jason Ray Burchett
JDJordan M. Dailey
Jordan M. Dailey
SKSydney A. Kee
Sydney A. Kee
DPDestiny T Pryor
Destiny T Pryor
AKAditya Kotha
Aditya Kotha
JRJohn Joseph Ryan
John Joseph Ryan
The incidence of allergic disease has grown tremendously in the past three generations. While current treatments are effective for some, there is considerable unmet need. Mast cells are critical effectors of allergic inflammation. Their secreted mediators and the receptors for these mediators have long been the target of allergy therapy. Recent drugs have moved a step earlier in mast cell activation, blocking IgE, IL-4, and IL-13 interactions with their receptors. In this review, we summarize the latest therapies targeting mast cells as well as new drugs in clinical trials. In addition, we offer support for repurposing FDA-approved drugs to target mast cells in new ways. With a multitude of highly selective drugs available for cancer, autoimmunity, and metabolic disorders, drug repurposing offers optimism for the future of allergy therapy.

1 November 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
MRMeghan L. Rudd
Meghan L. Rudd
ATAlymarie Tua-Smith
Alymarie Tua-Smith
DSDavid B. Straus
David B. Straus
Thymocyte development is shaped by signals from the T-cell antigen receptor. The strength of receptor signaling determines developmental progression as well as deletion of self-reactive T cells. Receptor stimulation of the extracellular signal-regulated kinase (ERK) pathway plays an important regulatory role during thymocyte development. However, it is unclear how differences in receptor signaling are translated into distinctive activation of the ERK pathway. We have investigated the potential role of the Lck tyrosine kinase in regulating intracellular signaling during thymocyte development. While Lck is known to be critical for initial T-cell receptor signaling events, it may have an independent role in regulating intracellular signaling through the function of its SH3 domain. To determine whether such a regulatory mechanism functions during thymocyte development, we generated mice in which the normal lck allele is replaced with an lck SH3 domain mutant. Analysis of these mice revealed that both early thymocyte development and maturation of CD4(+) and CD8(+) lineages is impaired. Investigation of thymocyte responses to antigen receptor stimulation showed a significant reduction in proliferation and ERK pathway activation, although initial signaling events were intact. These findings indicate that Lck SH3 domain function may provide a means to independently couple receptor signaling to regulation of the ERK pathway during thymocyte development.

1 January 2022 in Cellular Immunology
Verified
Journal Article
Closed access
DSDavid B. Straus
David B. Straus
DPDestiny Pryor
Destiny Pryor
THTamara T. Haque
Tamara T. Haque
SKSydney A. Kee
Sydney A. Kee
JDJordan M. Dailey
Jordan M. Dailey
JRJohn J. Ryan
John J. Ryan

21 February 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MTMarcela T. Taruselli
Marcela T. Taruselli
AQAmina Abdul Qayum
Amina Abdul Qayum
DADaniel Abebayehu
Daniel Abebayehu
HCHeather L. Caslin
Heather L. Caslin
JDJordan M. Dailey
Jordan M. Dailey
JRJohn Joseph Ryan
John Joseph Ryan
IL-33 is an inflammatory cytokine that promotes allergic disease by activating group 2 innate lymphoid cells, Th2 cells, and mast cells. IL-33 is increased in asthmatics, and its blockade suppresses asthma-like inflammation in mouse models. Homeostatic control of IL-33 signaling is poorly understood. Because the IL-33 receptor, ST2, acts via cascades used by the TLR family, similar feedback mechanisms may exist. MicroRNA (miR)-146a is induced by LPS-mediated TLR4 signaling and serves as a feedback inhibitor. Therefore, we explored whether miR-146a has a role in IL-33 signaling. IL-33 induced cellular and exosomal miR-146a expression in mouse bone marrow–derived mast cells (BMMCs). BMMCs transfected with a miR-146a antagonist or derived from miR-146a knockout mice showed enhanced cytokine expression in response to IL-33, suggesting that miR-146a is a negative regulator of IL-33–ST2 signaling. In vivo, miR-146a expression in plasma exosomes was elevated after i.p. injection of IL-33 in wild-type but not mast cell–deficient KitW-sh/W-sh mice. Finally, KitW-sh/W-sh mice acutely reconstituted with miR-146a knockout BMMCs prior to IL-33 challenge had elevated plasma IL-6 levels compared with littermates receiving wild-type BMMCs. These results support the hypothesis that miR-146a is a feedback regulator of IL-33–mediated mast cell functions associated with allergic disease.

14 July 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JDJordan M. Dailey
Jordan M. Dailey
SKSydney A Kee
Sydney A Kee
ATAnuj Tharakan
Anuj Tharakan
AKAslamuzzaman Kazi
Aslamuzzaman Kazi
JBJason R. Burchett
Jason R. Burchett
JRJohn Joseph Ryan
John Joseph Ryan
IgE-mediated mast cell activation is a driving force in allergic disease in need of novel interventions. Statins, long used to lower serum cholesterol, have been shown in multiple large-cohort studies to reduce asthma severity. We previously found that statins inhibit IgE-induced mast cell function, but these effects varied widely among mouse strains and human donors, likely due to the upregulation of the statin target, 3-hydroxy-3-methylgutaryl-CoA reductase. Statin inhibition of mast cell function appeared to be mediated not by cholesterol reduction but by suppressing protein isoprenylation events that use cholesterol pathway intermediates. Therefore, we sought to circumvent statin resistance by targeting isoprenylation. Using genetic depletion of the isoprenylation enzymes farnesyltransferase and geranylgeranyl transferase 1 or their substrate K-Ras, we show a significant reduction in FcεRI-mediated degranulation and cytokine production. Furthermore, similar effects were observed with pharmacological inhibition with the dual farnesyltransferase and geranylgeranyl transferase 1 inhibitor FGTI-2734. Our data indicate that both transferases must be inhibited to reduce mast cell function and that K-Ras is a critical isoprenylation target. Importantly, FGTI-2734 was effective in vivo, suppressing mast cell–dependent anaphylaxis, allergic pulmonary inflammation, and airway hyperresponsiveness. Collectively, these findings suggest that K-Ras is among the isoprenylation substrates critical for FcεRI-induced mast cell function and reveal isoprenylation as a new means of targeting allergic disease.